Compare XNET & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XNET | REPL |
|---|---|---|
| Founded | 2003 | 2015 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 358.4M | 407.1M |
| IPO Year | 2011 | 2018 |
| Metric | XNET | REPL |
|---|---|---|
| Price | $4.96 | $9.96 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $5.67 |
| AVG Volume (30 Days) | 236.3K | ★ 8.0M |
| Earning Date | 05-14-2026 | 05-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 5.25 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.29 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.02 | $1.50 |
| 52 Week High | $11.03 | $13.24 |
| Indicator | XNET | REPL |
|---|---|---|
| Relative Strength Index (RSI) | 33.53 | 77.88 |
| Support Level | N/A | $9.50 |
| Resistance Level | $6.12 | $10.67 |
| Average True Range (ATR) | 0.30 | 0.66 |
| MACD | -0.08 | 0.60 |
| Stochastic Oscillator | 0.85 | 90.83 |
Xunlei Ltd is a cloud-based acceleration technology company in China. The company operates a powerful internet platform in China based on cloud computing to provide users with quick and easy access to digital media content through its products and services, Xunlei Accelerator, and cloud acceleration subscription services. It is increasingly extending into mobile devices in part through potentially pre-installed acceleration products in mobile phones Xunlei has developed various value-added services to meet a fuller spectrum of its users' digital media content access and consumption needs.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.